ArticleBiotechnology for biofuels and bioproducts2026
Enhancement of growth and zeaxanthin accumulation via gene expression and metabolic pathways modulation in Chromochloris zofingiensis mutant CZ-Z12.
Article in Biotechnology for biofuels and bioproducts, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Antioxidant Compounds in Microalgae and Cyanobacteria: A Sustainable Source of Bioactive Molecules.Marine drugs · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundChromochloris zofingiensis is recognized as a promising resource for the production of carotenoids. However, current knowledge regarding its capacity for zeaxanthin accumulation remains limited, which restricts its potential for commercial application. The development of high-yielding strains and an understanding of the underlying metabolic and regulatory mechanisms are critical to advancing large-scale zeaxanthin production.
resultsIn this study, a novel zeaxanthin-enriched mutant CZ-Z12 was obtained using ethyl methyl sulfonate (EMS). CZ-Z12 displayed a rapid growth rate when cultivated heterotrophically. On Day 6, zeaxanthin content and total fatty acid (TFA) content reached 0.229% and 28.6% of dry weight (DW), representing a 4.1 and 1.9-fold increase compared to wild-type (WT), respectively. Differentially expressed genes (DEGs) were significantly enriched in pathways of ABC transporters, endogenous hormones signal transduction, nucleotide excision repair, glycolysis, purine and pyrimidine metabolism, glutathione metabolism, fatty acid and carotenoid biosynthesis. Genes encoding growth-related proteins, such as vegetative storage protein 2 (VSP2), deoxycytidine triphosphate pyrophosphatase 1 (DCTPP1), and fructose-bisphosphate aldolase (FBA), were up-regulated by 1.4, 1.7, and 2.5-fold, respectively. The key genes encoding enzymes in zeaxanthin biosynthesis, including glutathione reductase (GR), phytoene desaturase (PDS), and β-carotene hydroxylase (CHYb), were up-regulated by 3.1, 2.4, and 2.6-fold, respectively.
conclusionThese findings indicate that CZ-Z12 is an efficient strain for zeaxanthin production and highlight the potential for EMS mutagenesis for metabolic enhancement in heterotrophic C. zofingiensis. By modulating gene expression and key metabolic pathways, this study provides new insights and a practical strategy for improving carotenoid biosynthesis in microalgae, thereby supporting the feasible of large-scale, sustainable zeaxanthin production.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.